Trypanocidal Activity of Melamine-Based Nitroheterocycles

Antimicrobial Agents and Chemotherapy

Volumn 48, Issue 5, 2004, Pages 1733-1738

  Stewart, Mhairi L ^a   Bueno, Gorka Jimenez ^b   Baliani, Alessandro ^b   Klenke, Burkhard ^b   Brun, Reto ^c   Brock, Janice M ^a   Gilbert, Ian H ^b   Barrett, Michael P ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b CARDIFF UNIVERSITY   (United Kingdom)

^c SWISS TROPICAL AND PUBLIC HEALTH INSTITUTE   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

2 AMINO 5 (1 METHYL 5 NITRO 2 IMIDAZOLYL) 1,3,4 THIADIAZOLE; ACETYLCYSTEINE; ADENOSINE; BENZAMIDINE; CARRIER PROTEIN; DIMINAZENE ACETURATE; HETEROCYCLIC NITRO COMPOUND; MELAMINE; MELARSOPROL; NIFURTIMOX; NITROFURAN; P2 TRANSPORTER; PENTAMIDINE; PURINE DERIVATIVE; UNCLASSIFIED DRUG;

AFRICAN TRYPANOSOMIASIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIPROTOZOAL ACTIVITY; ARTICLE; CONTROLLED STUDY; CROSS LINKING; CYTOTOXICITY; DRUG DESIGN; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG SENSITIVITY; DRUG TRANSPORT; FEMALE; GENOTOXICITY; HUMAN; IC 50; MOUSE; NONHUMAN; NULL ALLELE; OXIDATIVE STRESS; PRIORITY JOURNAL; RAT; REDUCTION; TRYPANOSOMA BRUCEI;

ACETYLGLUCOSAMINE; ANIMALS; CELL LINE; DRUG DELIVERY SYSTEMS; FEMALE; HETEROCYCLIC COMPOUNDS; HUMANS; MICE; MOLECULAR CONFORMATION; MUTAGENS; MUTATION; NITRO COMPOUNDS; TRIAZINES; TRYPANOCIDAL AGENTS; TRYPANOSOMA BRUCEI BRUCEI; TRYPANOSOMA BRUCEI RHODESIENSE;

EID: 2142821417     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.48.5.1733-1738.2004     Document Type: Article

References (38)

1. Apted, F. I. C. 1960. Nitrofurazone in the treatment of sleeping sickness due to Trypanosoma rhodesiense. Trans. R. Soc. Trop. Med. Hyg. 54:225-228.
2. Aruoma, O. I., B. Halliwell, B. M. Hoey, and J. Butler. 1989. The antioxidant action of N-acetylcysteine: its reaction with hydrogen peroxide, hydroxyl radical, superoxide, and hypochlorous acid. Free Radic. Biol. Med. 6:593-597.
3. Baltz, T., D. Baltz, C. Giroud, and J. Crockett. 1985. Cultivation in a semidefined medium of animal infective forms of Trypanosoma brucei, T. equiperdum, T. evansi, T. rhodesiense, and T. gambiense. EMBO J. 4:1273-1277.
4. Barrett, M. P., and A. H. Fairlamb. 1999. The biochemical basis of arsenical-diamidine cross-resistance in African trypanosomes. Parasitol. Today 15:136-140.
5. Barrett, M. P., A. H. Fairlamb, B. Rousseau, G. Chauviere, and J. Perie. 2000. Uptake of the nitroimidazole drug megazol by African trypanosomes. Biochem. Pharmacol. 59:615-620.
6. Barrett, M. P., and I. H. Gilbert. 2002. Perspectives for new drugs against trypanosomiasis and leishmaniasis. Curr. Top. Med. Chem. 2:471-482.
7. Barrett, M. P., R. J. S. Burchmore, A. Stich, J. O. Lazzari, A. C. Frasch, J. J. Cazzulo, and S. Krishna. 2003. The trypanosomiases: divergent parasitic diseases arising from a common genus. Lancet 362:1469-1480.
8. Borowy, N. K., R. T. Nelson, H. Hirumi, R. Brun, H. K. Waithaka, D. Schwartz, and A. Polak. 1988. Ro 15-0216: a nitroimidazole compound active in vitro against human and animal pathogenic African trypanosomes. Ann. Trop. Med. Parasitol. 82:13-19.
9. Bouteille, B., A. Marie-Daragon, G. Chauviere, C. de Albuquerque, B. Enanga, M. L. Darde, J. M. Vallat, J. Perie, and M. Dumas. 1995. Effect of megazol on Trypanosoma brucei brucei acute and subacute infections in Swiss mice. Acta Trop. 60:73-80.
10. Brun, R., R. Schumacher, C. Schmid, C. Kunz, and C. Burri. 2001. The phenomenon of treatment failures in human African trypanosomiasis. Trop. Med. Int. Health 6:906-914.
11. Carter, N. S., and A. H. Fairlamb. 1993. Arsenical-resistant trypanosomes lack an unusual adenosine transporter. Nature 361:173-175.
12. Cotgreave, I. A. 1997. N-Acetylcysteine: pharmacological considerations and experimental and clinical applications. Adv. Pharmacol. 38:205-227.
13. Cunningham, M. P., and K. Vickerman. 1962. Antigenic analysis in the Trypanosoma brucei group using the agglutination reaction Trans. R. Soc. Trop. Med. Hyg. 56:48-59.
14. de Koning, H. P., and S. M. Jarvis. 1999. Adenosine transporters in blood-stream forms of Trypanosoma brucei brucei: substrate recognition motifs and affinity for trypanocidal drugs. Mol. Pharmacol. 56:1162-1170.
15. de Koning, H. P. 2001. Uptake of pentamidine in Trypanosoma brucei brucei is mediated by three distinct transporters: Implications for cross-resistance with arsenicals. Mol. Pharmacol. 59:586-592.
16. Docampo, R., and Stoppani, A. O. M. 1979. Generation of superoxide anion and hydrogen peroxide induced by nifurtimox in Trypanosoma cruzi. Arch. Biochem. Biophys. 197:317-321.
17. Enanga, B., M. Keita, G. Chauviere, M. Dumas, and B. Bouteille. 1998. Megazol combined with suramin: a chemotherapy regimen which reversed the CNS pathology in a model of human African trypanosomiasis in mice. Trop. Med. Int. Health 3:736-741.
18. Enanga, B., M. Ariyanayagam, M. Stewart, and M. P. Barrett. 2003. Activity of megazol, a trypanocidal nitroimidazole, is associated with DNA damage. Antimicrob. Agents Chemother. 47:3368-3370.
19. Evens, F., K. Niemegeers, and A. Packchanian. 1957. Nitrofurazone therapy of Trypanosoma gambiense sleeping sickness in man. Am. J. Trop. Med. Hyg. 6:665-678.
20. Ferreira, R. C., and L. C. Ferreira. 1986. CL 64,855, a potent anti-Trypanosoma cruzi drug, is also mutagenic in the Salmonella/microsome assay. Mem. Inst. Oswaldo-Cruz 81:49-52.
21. Hasne, M.-P., and M. P. Barrett. 2000. Drug uptake via nutrient transporters in Trypanosoma brucei. J. Appl. Microbiol. 89:697-701.
22. Hirumi, H., and K. Hirumi. 1989. Continuous cultivation of Trypanosoma brucei brucei bloodstream forms in a medium containing a low concentration of serum protein without feeder cell layers. J. Parasitol. 75:985-989.
23. Klenke, B., M. Stewart, R. Brun, M. P. Barrett, and I. H. Gilbert. 2001. Synthesis and biological evaluation of s-triazine substituted polyamines as potential new anti-trypanosomal drugs. J. Med. Chem. 44:3440-3452.
24. Lanham, S. M., and D. G. Godfrey. 1970. Isolation of salivarian trypanosomes from man and other mammals using DEAE-cellulose. Exp. Parasitol. 28:521-534.
25. Legros, D., G. Ollivier, M. Gastellu-Etchegorry, C. Paquet, C. Burri, J. Jannin, and P. Buscher. 2002. Treatment of human African trypanosomiasis: present situation and needs for research and development. Lancet Infect. Dis. 2:437-440.
26. Marton, L. J., and A. E. Pegg. 1995. Polyamines as targets for therapeutic intervention. Annu. Rev. Pharmacol. Toxicol. 35:55-91.
27. Maser, P., C. Sutterlin, A. Kralli, and R. Kaminsky. 1999. A nucleoside transporter from Trypanosoma brucei involved in drug resistance. Science 285:242-244.
28. Matovu, E., M. L. Stewart, F. Geiser, R. Brun, P. Mäser, L. M. P. Wallace, R. J. S. Burchmore, K. K. C. Enyaru, M. P. Barrett, R. Kaminsky, T. Seebeck, and H. P. de Koning. 2003. The roles of the Trypanosoma brucei P2 adenosine transporter (TbATI) in drug uptake and resistance determined through gene knockout. Eukaryot. Cell 2:1003-1008.
29. McCulloch, R., and J. D. Barry. 1999. A role for RAD51 and homologous recombination in Trypanosoma brucei antigenic variation. Genes Dev. 13:2875-2888.
30. Millet, R., L. Maes, V. Landry, C. Sergheraert, and E. Davioud-Charvet. 2002. Antitrypanosomal activities and cytotoxicity of 5-nitro-2-furancarbohydrazides. Bioorg. Med. Chem. Lett. 12:3601-3604.
31. Moreno, S. N. J., Mason, R. P., and Docampo, R. 1984. Reduction of nifurtimox and nitrofurantoin by intact rat liver mitochondria. Evidence of an outer membrane-located nitroreductase. J. Biol. Chem. 259:6298-6305.
32. Muller, S., G. H. Coombs, and R. D. Walter. 2001. Targeting polyamines of parasitic protozoa in chemotherapy. Trends Parasitol. 17:242-249.
33. Pepin, J., F. Milord, F. Meurice, L. Ethier, L. Loko, and B. Mpia. 1992. High-dose nifurtimox for arseno-resistant Trypanosoma brucei gambiense sleeping sickness: an open trial in central Zaire. Trans. R. Soc. Trop. Med. Hyg. 86:254-256.
34. Poli, P., M. Aline de Mello, A. Buschini, R. A. Mortara, C. Northfleet de Albuquerque, S. da Silva, C. Rossi, and T. M. Zucchi. 2002. Cytotoxic and genotoxic effects of megazol, an anti-Chagas' disease drug, assessed by different short-term tests. Biochem. Pharmacol. 64:1617-1627.
35. Raz, B., M. Iten, Y. Grether-Buhler, R. Kaminsky, and R. Brun. 1997. The Alamar Blue assay to determine drug sensitivity of African trypanosomes (T. b. rhodesiense and T. b. gambiense) in vitro. Acta Trop. 68:139-147.
36. Rodriques-Coura, J., and S. L. de Castro. 2002. A critical review on Chagas disease chemotherapy. Mem. Inst. Oswaldo-Cruz 97:3-24.
37. Sanchez, M. A., R. Tryon, J. Green, I. Boor, and S. M. Landfear. 2002. Six related nucleoside nucleobase transporters from Trypanosoma brucei exhibit distinct biochemical functions. J. Biol. Chem. 277:21499-21504.
38. Tye, C. K., G. Kasinathan, M. P. Barrett, R. Brun, V. E. Doyle, A. H. Fairlamb, R. Weaver, and. I. H. Gilbert. 1998. An approach to use an unusual adenosine transporter to selectively deliver polyamine analogues to trypanosomes. Bioorg. Med. Chem. Lett. 8:811-816.